Menu
Search
|

Menu

Close
X

Vical Inc VICL.OQ (NASDAQ Stock Exchange Capital Market)

0.72 USD
-0.00 (-0.00%)
As of Jul 19
Previous Close 0.72
Open 0.74
Volume 281,665
3m Avg Volume 52,970
Today’s High 0.76
Today’s Low 0.72
52 Week High 1.47
52 Week Low 0.72
Shares Outstanding (mil) 22.84
Market Capitalization (mil) 16.45
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
2
FY17
14
FY16
15
EPS (USD)
FY19
-0.315
FY18
-0.744
FY17
-1.031
FY16
-0.889
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.52
Price to Sales (TTM)
vs sector
96.17
7.97
Price to Book (MRQ)
vs sector
0.40
4.45
Price to Cash Flow (TTM)
vs sector
--
24.33
Total Debt to Equity (MRQ)
vs sector
0.00
17.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.58
Return on Investment (TTM)
vs sector
-25.49
12.69
Return on Equity (TTM)
vs sector
-25.49
17.17

EXECUTIVE LEADERSHIP

R. Douglas
Independent Chairman of the Board, Since 1999
Salary: --
Bonus: --
Vijay Samant
President, Chief Executive Officer, Director, Since 2014
Salary: $557,000.00
Bonus: $264,000.00
Anthony Ramos
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Since 2017
Salary: $232,185.00
Bonus: $60,000.00
Thomas Shenk
Director, Since 2015
Salary: --
Bonus: --
Richard Beleson
Independent Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10390 Pacific Center Ct
SAN DIEGO   CA   92121-4340

Phone: +1858.6461100

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

SPONSORED STORIES